Harvard Medical School professor Stuart Orkin has received the 2026 Breakthrough Prize in Life Sciences for research that led to a cure for sickle cell disease and beta-thalassemia. Orkin shares the award with NIH researcher Swee Lay Thein.
The scientists determined the mechanism behind the body's transition from fetal hemoglobin to adult hemoglobin and validated it as a therapeutic target. Their discovery formed the basis for the world's first FDA-approved CRISPR-based gene therapy in 2024.
The treatment represents a major advance for patients with sickle cell disease, a genetic disorder affecting red blood cells that causes pain, organ damage, and reduced lifespan. Beta-thalassemia is another inherited blood disorder addressed by the therapy.
The Breakthrough Prize recognizes transformative advances in fundamental science. Orkin's work demonstrates how basic research can lead to clinical applications that significantly improve patient outcomes.